Biopharmx corp (BPMX)
Income statement / Yearly
Jan'20Jan'19Jan'18Jan'17Jan'16Dec'14Dec'13Sep'13Dec'12Sep'12Sep'11
Revenues, net

-

57

73

-

-

-

-

-

-

-

-

Cost of goods sold

-

83

250

-

-

-

-

-

-

-

-

Revenues, net

-

-

-

100

64

-

-

-

-

-

-

Cost of goods sold

-

-

-

516

237

-

-

-

-

-

-

Gross margin

-

-26

-177

-416

-173

-

-

-

-

-

-

REVENUES

-

-

-

-

-

-

-

0

-

0

0

Operating expenses:
Research and development

4,690

9,079

9,140

10,158

5,702

2,519

671

-

31

-

-

Sales and marketing

714

2,157

2,415

3,198

5,109

2,299

132

-

9

-

-

Professional fees

-

-

-

-

-

-

-

51

-

27

55

General and administrative

4,282

5,244

5,144

4,654

4,174

2,953

711

1

43

0

3

Total operating expenses

9,686

16,480

16,699

18,010

14,985

7,771

1,514

52

83

27

59

Interest Income

-

-

-

-

-

-

-

0

-

0

0

LOSS BEFORE PROVISION FOR INCOME TAX

-

-

-

-

-

-

-

-52

-

-27

-

PROVISION FOR INCOME TAX

-

-

-

-

-

-

-

0

-

0

-

PROVISION FOR INCOME TAX

-

-

-

-

-

-

-

-

-

-

0

Loss from operations

-9,686

-16,506

-16,876

-18,426

-15,158

-7,771

-1,514

-52

-

-27

-59

Change in fair value of warrant and stock liabilities

291

28

-

-

-

-

-

-

-

-

-

Change in fair value of warrant liability

-

-

364

163

-

-

-

-

-

-

-

Other income (expense), net

-290

-778

-126

-141

-436

40

-

-

-

-

-

Loss before provision for income taxes

-9,700

-17,300

-16,638

-18,404

-15,594

-7,807

-

-

-

-

-59

Interest expense

-

-

-

-

-

76

-

-

5

-

-

Provision for income taxes

2

2

2

2

4

-

-

-

-

-

-

Interest expense, net

-

-

-

-

-

-

-74

-

-

-

-

Net loss and comprehensive loss

-9,687

-17,258

-16,640

-18,406

-15,598

-7,807

-1,588

-

-88

-

-

Accretion on Series A convertible preferred stock

-

-

-

-

202

163

-

-

-

-

-

Deemed dividend on Series A convertible preferred stock

-

-

-

-

201

159

-

-

-

-

-

Deemed dividend on Series A convertible preferred stock

-

-

-

126

-

-

-

-

-

-

-

Net loss available to common stockholders

-

-

-

-18,532

-16,001

-8,129

-1,588

-

-

-

-

Net loss available to common stockholders

-

-

-

-

-

-

-

-52

-83

-27

-59

Basic and diluted net loss per share

-0.75

-2.23

-0.19

-0.52

-0.89

-0.80

-0.22

0.00

-0.01

0.00

-0.01

Shares used in computing basic and diluted net loss per share

12,921

7,727

85,900

35,806

17,950

10,217

7,119

-

7,400

-

-

WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING: BASIC AND DILUTED

-

-

-

-

-

-

-

9,000

-

9,000

8,210